Simulations Plus (SLP) +29% Surge: Altaris Acquisition Provides Clear Catalyst
Key Takeaways
- Simulations Plus (SLP) surged approximately 29% over the last 30 days, climbing from $14.10 on May 19 to $18.24 by June 18, 2026.
- The definitive acquisition agreement with Altaris for $18.50 per share in cash, announced in mid-June, served as the primary catalyst for the sharp upward move.
- Over the last quarter, SLP has rallied roughly 56% from its 52-week low of $11.09 in late March, reflecting a broader recovery narrative.
- Key developments including an NVIDIA collaboration on AI-accelerated modeling, a funded research partnership with Lonza and the FDA, and a fiscal Q2 earnings beat all contributed to renewed investor confidence.
- Analyst sentiment remains mixed, with several firms downgrading the stock to Hold or Market Perform following the acquisition announcement, aligning price targets near the buyout price.
A Closer Look at Simulations Plus (SLP)
Simulations Plus, Inc. is a specialized provider of model-informed and AI-accelerated drug development software and consulting services. Headquartered in Research Triangle Park, North Carolina, the company operates through two segments: Software and Services. Its flagship products — including GastroPlus, ADMET Predictor, DILIsym, and the MonolixSuite — are used by pharmaceutical, biotechnology, and regulatory agencies worldwide to simulate drug absorption, predict molecular properties, and model toxicity risks. By integrating artificial intelligence and machine learning into biosimulation workflows, Simulations Plus helps clients accelerate drug discovery, reduce clinical trial costs, and strengthen regulatory submissions. The company's niche positioning at the intersection of healthcare, technology, and AI has made it a closely watched name among investors seeking exposure to AI-driven life sciences innovation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
SLP Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, SLP shares have risen from an adjusted closing price of $14.10 on May 19, 2026, to $18.24 on June 18, 2026 — a gain of approximately 29.4%. The rally accelerated sharply in the final week of the period following the announcement that affiliates of Altaris would acquire the company for $18.50 per share in an all-cash transaction. Prior to that announcement, the stock had already been recovering steadily from deeply oversold levels, supported by a series of positive operational developments.
Zooming out to the last quarter, the performance is even more pronounced. From the 52-week low of $11.09 reached on March 30, 2026, SLP has climbed roughly 64% to current levels. The quarterly trend reflects a multi-month recovery after a punishing drawdown that began in mid-2025, when a severe revenue guidance cut, a $77.2 million impairment charge, and an auditor dispute triggered a collapse from above $30 to the low teens. The recent rebound has been fueled by improving fundamentals, strategic partnerships, and ultimately the acquisition premium.
What Drove SLP Stock Price in the Last 30 Days
The single most powerful catalyst during the 30-day window was the June 16 announcement that Simulations Plus had entered into a definitive agreement to be acquired by affiliates of Altaris for $18.50 per share in cash, valuing the company at approximately $375 million. The stock, which had been trading around $16.30 prior to the announcement, immediately repriced toward the buyout level, generating a double-digit percentage surge in a matter of days.
Before the acquisition news, several other developments had already been building positive momentum. In early May, Simulations Plus and NVDA (NVIDIA) launched a technical collaboration to scale GPU-accelerated, AI-assisted modeling workflows — a partnership that resonated strongly with investors focused on AI-driven healthcare innovation. In late April, the company announced a funded research collaboration with LZAGY (Lonza Group) and the U.S. FDA to develop predictive frameworks for complex oral drug products, reinforcing the company's regulatory relevance. Additionally, the company's fiscal Q2 2026 earnings, reported in early April, beat consensus estimates on both revenue and EPS, providing fundamental validation after months of negative sentiment.
What Drove SLP Stock Performance Over the Last Quarter
The broader quarterly narrative is one of recovery from a deep crisis of confidence. In June 2025, SLP shares plummeted after the company slashed its fiscal 2025 revenue outlook, disclosed a massive goodwill impairment charge, and became embroiled in an auditor dispute. The stock, which had traded above $30, collapsed into the mid-teens and continued grinding lower through early 2026, ultimately bottoming at $11.09 on March 30.
The turnaround began with the fiscal Q2 2026 earnings release on April 9, which showed revenue of $24.29 million and adjusted EPS of $0.17 — both exceeding analyst expectations. This was followed by a steady stream of positive announcements: the completion of the 2026 Spring School global training initiative, the Lonza-FDA collaboration, and the high-profile NVIDIA partnership. These events collectively signaled that Simulations Plus remained operationally sound and strategically relevant despite the prior year's turmoil. The Altaris buyout offer then crystallized the recovery, providing a concrete valuation floor and triggering the final leg upward. From what I see, the sequence of events highlights how operational progress can set the stage for a deal-driven re-rating.
Using Tickeron’s Trending AI Robots for Market Context
In a market increasingly shaped by algorithmic strategies, I often turn to Tickeron’s Trending AI Robots page to get a curated view of the platform's top-performing AI-powered trading bots. Tickeron hosts hundreds of bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance metrics. Only the most relevant and consistently high-performing bots are featured in this section, allowing users to quickly identify AI-driven trading approaches that align with current market conditions. Whether focused on short-term momentum, swing trading, or longer-term trend following, these bots provide a data-driven complement to traditional analysis. Exploring the Trending AI Robots page can help investors discover automated strategies that match their trading style and risk tolerance. I’m watching this closely as a way to cross-check broader sentiment around names like SLP.
SLP Stock Forecast Drivers: What Investors Should Watch Next
With the Altaris acquisition pending, the primary focus for SLP shareholders shifts to the deal's closing timeline and any potential regulatory or shareholder approval hurdles. The transaction is expected to close by February 10, 2027, and the founders have already agreed to vote in favor. Until closing, SLP's stock price is likely to trade in a narrow range around the $18.50 offer price, with deviations reflecting any perceived risks to deal completion.
Beyond the acquisition, investors should monitor the company's upcoming earnings report, estimated for July 9, 2026, which will provide insight into whether the operational momentum seen in Q2 has continued. Broader industry trends — including biotech funding cycles, FDA regulatory shifts toward AI-assisted drug development tools, and demand for biosimulation software — remain relevant to understanding the company's standalone value. Macroeconomic factors such as interest rate policy and healthcare sector capital flows may also influence sentiment around small-cap life sciences names. As always, investors should conduct their own due diligence and consider their individual financial circumstances before making any investment decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SLP sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for SLP moved above the 200-day moving average on June 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on SLP as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLP advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 174 cases where SLP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for SLP moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for SLP turned negative on July 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.667) is normal, around the industry mean (7.391). P/E Ratio (45.825) is within average values for comparable stocks, (51.382). SLP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.533). Dividend Yield (0.004) settles around the average of (0.044) among similar stocks. P/S Ratio (4.515) is also within normal values, averaging (5.793).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of software for use in pharmaceutical research
Industry ServicestotheHealthIndustry
Advertisement